Satyam Singh

Satyam Singh

Auto-generated profile, based on publicly available information

Satyam Singh

Indian Institute of Technology Indore Khandwa Road

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2020 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
SSSatyam Singh
Satyam Singh
Md Fulbabu SkMd Fulbabu Sk
Md Fulbabu Sk
ASAvinash Sonawane
Avinash Sonawane
PKParimal Kar
Parimal Kar
SSSushabhan Sadhukhan
Sushabhan Sadhukhan
The sudden outburst of Coronavirus disease (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) poses a massive threat to global public health. Currently, no therapeutic drug or vaccine exists to treat COVID-19. Due to the time taking process of new drug development, drug repurposing might be the only viable solution to tackle COVID-19. RNA‐dependent RNA polymerase (RdRp) catalyzes SARS-CoV-2 RNA replication and hence, is an obvious target for antiviral drug design. Interestingly, several plant-derived polyphenols effectively inhibit the RdRp of other RNA viruses. More importantly, polyphenols have been used as dietary supplementations for a long time and played beneficial roles in immune homeostasis. We were curious to study the binding of polyphenols with SARS-CoV-2 RdRp and assess their potential to treat COVID-19. Herein, we made a library of polyphenols that have shown substantial therapeutic effects against various diseases. They were successfully docked in the catalytic pocket of RdRp. The investigation reveals that EGCG, theaflavin (TF1), theaflavin-3’-O-gallate (TF2a), theaflavin-3’-gallate (TF2b), theaflavin 3,3'-digallate (TF3), hesperidin, quercetagetin, and myricetin strongly bind to the active site of RdRp. Further, a 150-ns molecular dynamic simulation revealed that EGCG, TF2a, TF2b, TF3 result in highly stable bound conformations with RdRp. The binding free energy components calculated by the MM-PBSA also confirm the stability of the complexes. We also performed a detailed analysis of ADME prediction, toxicity prediction, and target analysis for their druggability. Overall, our results suggest that EGCG, TF2a, TF2b, TF3 can inhibit RdRp and represent an effective therapy for COVID-19. Communicated by Ramaswamy H. Sarma

2 May 2022 in Critical Reviews in Food Science and Nutrition
Verified
Journal Article
Closed access
RSRevathy Sahadevan
Revathy Sahadevan
SSSatyam Singh
Satyam Singh
A.Anupama .
Anupama .
SSSushabhan Sadhukhan
Sushabhan Sadhukhan
Natural products have been a bedrock for drug discovery for decades. (−)-Epigallocatechin-3-gallate (EGCG) is one of the widely studied natural polyphenolic compounds derived from green tea. It is the key component believed to be responsible for the medicinal value of green tea. Significant studies implemented in in vitro, in cellulo, and in vivo models have suggested its anti-oxidant, anti-cancer, anti-diabetic, anti-inflammatory, anti-microbial, neuroprotective activities etc. Despite having such a wide array of therapeutic potential and promising results in preclinical studies, its applicability to humans has encountered with rather limited success largely due to the poor bioavailability, poor membrane permeability, rapid metabolic clearance and lack of stability of EGCG. Therefore, novel techniques are warranted to address those limitations so that EGCG or its modified analogs can be used in the clinical setup. This review comprehensively covers different strategies such as structural modifications, nano-carriers as efficient drug delivery systems, synergistic studies with other bioactivities to improve the chemico-biological aspects (e.g., stability, bioavailability, permeability, etc.) of EGCG for its enhanced pharmacokinetics and pharmacological properties, eventually enhancing its therapeutic potentials. We think this review article will serve as a strong platform with comprehensive literature on the development of novel techniques to improve the bioavailability of EGCG so that it can be translated to the clinical applications.

14 June 2022 in RSC Advances
Verified
Journal Article
Open access
PDF file
SSSatyam Singh
Satyam Singh
RSRevathy Sahadevan
Revathy Sahadevan
RRRajarshi Roy
Rajarshi Roy
MBMainak Biswas
Mainak Biswas
PGPriya Ghosh
Priya Ghosh
SSSushabhan Sadhukhan
Sushabhan Sadhukhan
Among the synthesized 4′′-alkyl EGCG derivatives, 4′′-C 14 EGCG inhibited EGF stimulated phosphorylation of EGFR and its downstream signaling pathways, ERK and Akt. 4′′-C 14 EGCG showed significantly improved stability than EGCG and induced apoptosis.

19 August 2026 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
BNBhagyashri Soumya Nayak
Bhagyashri Soumya Nayak
SSSukanya Samanta
Sukanya Samanta
SSSayantan Sarkar
Sayantan Sarkar
SSSatyam Singh
Satyam Singh
SMSuman Mukhopadhyay
Suman Mukhopadhyay
ASAVINASH Sonawane
AVINASH Sonawane